NDC product
Olopatadine Hydrochloride
NDC 0536-1307 · Rugby Laboratories
Key facts
| Product NDC | 0536-1307 |
|---|---|
| Proprietary name | Olopatadine Hydrochloride |
| Nonproprietary name | Olopatadine Hydrochloride |
| Substances | OLOPATADINE HYDROCHLORIDE |
| Dosage form | SOLUTION/ DROPS |
| Route | OPHTHALMIC |
| Labeler | Rugby Laboratories |
| Product type | HUMAN OTC DRUG |
| Marketing category | ANDA |
| Application number | ANDA209752 |
| Pharmacologic classes | Decreased Histamine Release [PE], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], Histamine-1 Receptor Inhibitor [EPC], Mast Cell Stabilizer [EPC] |
| Marketing start | Jan 15, 2021 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: